Intermediate-Dose Cytarabine as Postinduction AML Therapy

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Acute myeloid leukemia (AML) is a significant hematologic malignancy.
• Postinduction chemotherapy plays a crucial role in AML treatment.
• Comparing different cytarabine dosing strategies is essential for optimizing patient outcomes.

Purpose of the Study:

• To evaluate the noninferiority of intermediate-dose cytarabine (IDAC) versus high-dose cytarabine (HDAC) in overall survival (OS).
• To assess the safety and toxicity profiles of IDAC compared to HDAC as postinduction therapy for AML.
• To determine the efficacy of IDAC in a specific adult patient cohort.

Main Methods:

• A randomized controlled trial was conducted involving patients aged 18-60 with newly diagnosed AML.
• Patients received either IDAC (1500 mg/m²/12 hours) or HDAC (3000 mg/m²/12 hours) postinduction.
• Overall survival (OS) was the primary endpoint, with analyses adjusted for European Leukemia Net (ELN) 2022 risk group, anthracycline use, induction response, and allogeneic stem cell transplantation (HSCT).

Main Results:

• At 5 years, OS was 59.3% for IDAC versus 57.5% for HDAC, demonstrating noninferiority (adjusted hazard ratio, 0.96; P=0.0042).
• No significant interaction was found between treatment effect and patient subgroups (e.g., ELN 2022 risk group).
• IDAC was associated with lower severity of myelosuppression and fewer related adverse events compared to HDAC.

Conclusions:

• Intermediate-dose cytarabine (IDAC) offers noninferior overall survival outcomes compared to high-dose cytarabine (HDAC) in newly diagnosed AML patients.
• IDAC demonstrates a favorable safety profile with similar or reduced toxicities.
• These findings support IDAC as an effective and potentially safer postinduction therapy option for AML.